Overview
Developing a new drug is a lengthy and costly process, often taking more than a decade and costing up to $2.6 billion; yet, fewer than 1 in 20 candidates entering clinical trials achieve FDA approval. To help address this challenge, the integration of causal AI and mechanistic modeling is offering a more predictive and efficient approach to drug development. Ansys has partnered with healthtech company Nova In Silico to advance this capability by combining Nova’s Jinko trial simulation platform with Ansys Granta Data Management. Together, they’re enabling the creation of digital twins for In Silico Clinical Trials (ISCT)—a powerful method for reducing R&D costs, accelerating development timelines, and improving the chances of clinical success in the biopharma sector.
.
What you will learn :
- How in silico clinical trials and digital twins can help predict drug outcomes earlier in development, reducing the need for costly physical trials
- The role of causal AI and mechanistic modeling in improving the accuracy and efficiency of trial simulations
- How the integration of platforms like Jinko and Ansys Granta enables pharmaceutical companies to streamline R&D, lower risk, and boost clinical success rates
Speakers
François-Henri Boissel - Nova In Silico
Date / Time:August 27, 2025
11:00 AM EDT
Venue:Virtual
- Cost:
No reviews available for this learning resource.
